// CHAPTER 01
AI-assisted dermatology,
earned the hard way.
An AI triage and prescribing platform built from day one for Utah’s AI Learning Lab.
// CHAPTER 02
October 5, 2026.
Utah opened the door.
The first U.S. state to authorize AI-issued prescriptions. A formal sandbox. A public process. We intend to walk through it.
// CHAPTER 03
Rosacea first.
Narrow. Visual. Low risk. Sixteen million Americans. The same formula that earned the first approval.
SCROLL TO CONTINUE
// 01 — THE OPENING
The door just opened.
On October 5, 2026, Utah became the first U.S. state to authorize artificial intelligence to issue first-time prescriptions. Nolla Health’s agreement with Utah’s Office of Artificial Intelligence Policy (OAIP) and Division of Professional Licensing cleared AI-issued prescriptions for topical acne treatments under a staged pilot with decreasing physician oversight.
36.5days
AVG WAIT / NEW DERMATOLOGY APPT, NATIONAL (AMN 2025)
61days
AVG DERMATOLOGY WAIT / UTAH (PER NOLLA HEALTH)
$150–200
UNINSURED FIRST DERMATOLOGY VISIT
16M
AMERICANS LIVING WITH ROSACEA
// 02 — THE PROTOCOL
Rosacea first. Narrow, visual, low risk.
First-line rosacea treatments are prescription-only topicals: metronidazole, azelaic acid 15%, ivermectin 1%, brimonidine, oxymetazoline. Chronic condition, subscription fit, mild side-effect profile.
/ 01
Photo intake
10 to 15 minutes on a phone camera. Facial photos plus medical history. No appointment, no waiting room.
/ 02
AI assessment
Severity scored against physician-approved protocols. Fixed formulary only. Anything uncertain escalates to a licensed physician. The AI never improvises.
/ 03
Staged oversight
Every prescription reviewed by a Utah-licensed physician for the first 100 patients. Steps down to retrospective review only with written state approval.
/ 04
Pharmacy fulfillment
Approved prescriptions route to a licensed pharmacy. Refills and progress tracking continue inside the subscription.
// HARD GUARDRAILS
- Topical treatments only. No oral medications, no controlled substances.
- Fixed formulary. The AI cannot prescribe outside physician-approved options.
- Adults 18 and older only.
- Utah patients only during the sandbox pilot.
// 03 — THE PATHWAY
Utah’s AI Learning Lab.
A formal regulatory relief program for AI in healthcare. Public process, no application fee, 12-month agreements with one possible 12-month extension. Monthly safety reporting, quarterly public reports.
/ 01
Informal conversation
Introductory discussion with OAIP. No documents required.
/ 02
Short proposal
2 to 10 pages, scored against a published rubric.
/ 03
Extended proposal
20 to 50+ page clinical and technical dossier with external clinical review.
/ 04
Demo + agreements
Live product demo, red-teaming, privacy, customer, and insurance agreements.
/ 05
Signed agreement
Regulatory relief signed. The pilot deploys under sandbox protections.
// PRECEDENT PILOTS
- Nolla Health — first AI-issued first-time prescriptions in the U.S., topical acne, October 2026
- Doctronic — AI prescription renewals for chronic conditions, live since January 2026
- August AI — AI-assisted renewals for diabetes and cardiovascular medications, October 2026
- Legion Health — AI refill pilot for psychiatric maintenance medications
// 04 — THE MODEL
Subscription care, honest unit economics.
$14.99/mo
MODELED PRICE. COMPS: CUROLOGY ~$19.95, APOSTROPHE ~$25, MUSELY ~$32, HERS ~$44
$30–70
CUSTOMER ACQUISITION COST, PAID SOCIAL (BEAUTY/HEALTH DTC)
~4x
MODELED LTV-TO-CAC AT 7% MONTHLY CHURN
~1,100
STEADY SUBSCRIBERS TO OPERATING BREAK-EVEN
Utah-only patient base during the sandbox pilot. Multi-state expansion follows successful pilot completion and separate state authorization.
// 05 — USE OF FUNDS
Year-one budget, benchmarked.
Planning benchmarks compiled from public sources, October 2026: insurance broker data, telehealth physician market rates, DTC acquisition benchmarks, OAIP application requirements.
| LINE ITEM | AMOUNT | BASIS |
|---|---|---|
| TOTAL YEAR-ONE BUDGET |
Planning benchmarks, not vendor quotes. Insurance and legal are the widest ranges and get confirmed with broker and counsel quotes during pre-application.
// 06 — MILESTONES
The next 90 days.
D 01–14
Open the door
Request the informal conversation with OAIP. Confirm Wyoming entity good standing. Retain Utah healthcare regulatory counsel.
D 15–45
Build the clinical core
Recruit a Utah-licensed dermatologist as medical director. Lock the condition and formulary. Collect insurance broker quotes.
D 46–90
File and build
Submit the short proposal. Build the web intake MVP. Begin clinical validation. Register the foreign entity in Utah.
M 04–06
Agreement + launch
Extended proposal, external clinical review, live demo, signed agreement, staged pilot launch.
// KILL CRITERIA
- OAIP declines the condition or the relief request.
- Specialty malpractice quotes come back above $80,000 per year.
- No Utah-licensed dermatologist partner at a workable retainer.
- Counsel finds the corporate-practice structure unworkable.
// 07 — TEAM
Small team, serious oversight.
Drosia is built by operators and governed by physicians. The medical leadership seat is open and in active recruitment: a Utah-licensed dermatologist as founding medical director.
FOUNDER
Aaron Beasley
Awaken. Founder and operator across consumer health and marketplace products.
MEDICAL DIRECTOR
Recruiting
Utah-licensed dermatologist. Owns all clinical protocols and the formulary.
CLINICAL ADVISORS
In formation
Dermatology and AI-safety advisors to be named at application.
// STRUCTURE
- Awaken — Wyoming research and development company. Sandbox applicant and research sponsor.
- Uncut Rush — software publishing company. Builds and operates the Drosia platform.
- Drosia — planned patient-facing brand for the Utah pilot.
- Clinical decisions sit with licensed physicians, never with the operating companies.
// 08 — CLINICAL GOVERNANCE
Safety is the architecture.
The pilot is designed the way Utah’s sandbox requires: narrow scope, fixed formulary, staged physician oversight, and hard stops where the AI must defer.
/ 01
Physician-owned protocols
Every treatment pathway is written and approved by the medical director. The AI executes protocols; it does not invent them.
/ 02
Staged oversight
Proposed, mirroring Utah’s approved template: a physician reviews every prescription for the first 100 patients, then daily retrospective review, then weekly sample review. Each step-down only with written state approval.
/ 03
Hard-stop exclusions
Under 18, outside Utah, uncertain diagnosis, red-flag symptoms: the system stops and routes to a human. No exceptions, no overrides.
/ 04
Continuous reporting
Adverse events tracked and reported. Monthly safety reporting and quarterly public reports, per sandbox terms. Third-party evaluator access from day one.
// FORMULARY DISCIPLINE
- Topical generics only: metronidazole, azelaic acid 15%, ivermectin 1%. No oral medications, no controlled substances, ever.
- The AI cannot prescribe outside the physician-approved formulary. The constraint is technical, not procedural.
// 09 — DATA & PRIVACY
Patient data, handled like it matters.
Facial images and health histories are the most sensitive data a platform can hold. The defaults are set accordingly.
// COMMITMENTS
- HIPAA-aligned handling of all protected health information, with business associate agreements across vendors.
- Encryption in transit and at rest. Access limited to the care team on a need-to-know basis.
- Patient images are never sold, never used for advertising, and never used to train models without explicit opt-in consent.
- Patients can export and delete their data at any time.
Full privacy policy and terms of service publish before the pilot enrolls its first patient.
// 10 — SOURCES
Every claim, traceable.
- UTAH OAIP: AI REGULATORY RELIEF PROCESSOfficial application steps, no-fee application
- BECKER’S HOSPITAL REVIEWNolla approval, staged oversight, $4.99/mo, 175,000+ downloads
- PR NEWSWIRENolla Health announcement, October 5, 2026
- BUSINESS WIREAugust AI renewal pilot, 1,250 physician-reviewed decisions per class, $4 per renewal
- UTAH OAIP: DOCTRONIC PILOT PAGERenewal pilot status and compliance reporting
- AMN HEALTHCARE 2025 SURVEY36.5-day average dermatology wait nationally
- PMC (2026)Rosacea topical treatment review, ~16M Americans affected
- FIN VS FINDTC teledermatology pricing comparables
- VOUCH (2026)Startup E&O and cyber insurance benchmarks
- FIRST PAGE SAGE (2026)Patient acquisition cost benchmarks
// CONTACT
Owaiken
Owaiken is a research-stage project of Awaken, a Wyoming research and development company. Software development by Uncut Rush. Research stage. Not authorized to prescribe medication in any state.
FOUNDER
Aaron Beasley
Awaken
RESEARCH STAGE. NOT YET AUTHORIZED. NOT PRESCRIBING.